Effect of Exercise on Insulin Resistance



Status:Completed
Conditions:Endocrine, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - 75
Updated:11/8/2014
Start Date:September 2013
End Date:March 2014
Contact:Devon S Payne, BA
Email:devon.payne@alere.com
Phone:5037478132

Use our guide to learn which trials are right for you!

The purpose of this study is to evaluate the effect of exercise on Insulin Resistance (IR)
in subjects who do not routinely exercise and who are at risk of developing diabetes
(prediabetes).

It is estimated that approximately 30-90 people will participate in this study at three
study sites in the United States and United Kingdom.


Inclusion Criteria

1. Aged 18 to 75 years.

2. Meets one of the three diagnostic criteria listed below (based on screening results
or recorded result within one week of enrollment);

1. Fasting plasma or whole blood glucose (fasting defined as no caloric intake for
at least 8 hours): 100 ≤ 125 mg/dL (6.0-6.9 mmol/L)

2. HbA1c of 5.7% - 6.4% (39 - 46 mmol/mol)

3. 2-hour plasma glucose of 140-199 mg/dL (7.8-11.0 mmol/L) during an OGTT (as
described by the WHO using a glucose load of 75 g anhydrous glucose dissolved in
water)

3. No clinically significant adverse exercise response during the maximal graded
exercise test

Exclusion Criteria

1. Weight loss diet program or weight change (>10%) within the past 6 months

2. Daily physical activity of >10,000 steps per day (as measured during the interval
between visits 1 and 2)

3. Participates in deliberate structured exercise

4. Pregnant or intending to become pregnant

5. Cognitive or intellectual disability that prevents subject from providing informed
consent or following protocol instructions.

6. Unwillingness to participate in all study procedures

7. Inability to give blood through multiple venous phlebotomies or to have an
intravenous catheter

8. BMI greater than 40 kg/m2

9. Concurrent participation in another lifestyle modification trial

10. Diagnosis of diabetes based on any one of the following criteria:

1. Fasting plasma or whole blood glucose ≥ 126 mg/dL (7 mmol/L)

2. HbA1c of >6.5% (>47 mmol/mol)

3. 2-hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during an OGTT

11. Any pre-existing or newly discovered medical condition that is deemed likely to put
the subject at risk of injury during this trial. This may include but is not limited
to:

1. Clinically relevant vascular or cerebrovascular event (e.g. stroke, recurrent
transient ischemic attack (TIA), deep venous thrombosis or intracardiac
thrombi, clinically significant edema within the previous 6 months

2. Current use of anti-psychotic, anti-convulsant, anti-coagulant, sedative
medication, or cognition-enhancing medications

3. Current use of beta blockers (beta-adrenergic blocking agents)

4. Current or previous use (within the past year) of the following medications:
diabetes related medications or insulin; metformin; growth hormone; glucagon;
dipeptidyl peptidase-4(DPP-4) inhibitors (saxagliptin, stigagliptin);
glucagon-Like Peptide-1(GLP-1) mimetics (exenatide, liraglutide); sulfonylurea
medication or other potential confounding medications

5. Medical conditon which predetermines insulin resistance (e.g. Marfan syndrome /
severe Polycystic ovary syndrome (PCOS) / Cushing syndrome etc.).

6. Fasting triglycerides > 1000 mg/dL.
We found this trial at
1
site
Renton, Washington 98057
?
mi
from
Renton, WA
Click here to add this to my saved trials